An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
NCT ID: NCT05399368
Last Updated: 2024-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
229 participants
INTERVENTIONAL
2022-06-07
2024-05-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
NCT04271514
Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis
NCT03394677
Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
NCT03915496
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
NCT02950922
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
NCT06239311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RPT193 400 mg
RPT193 400 mg oral tablet administered daily for 16 weeks
RPT193
RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
RPT193 200 mg
RPT193 200 mg oral tablet administered daily for 16 weeks
RPT193
RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
RPT193 50 mg
RPT193 50 mg oral tablet administered daily for 16 weeks
RPT193
RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
Placebo
Matching placebo oral tablet administered daily for 16 weeks
Placebo
Nonactive placebo tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RPT193
RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
Placebo
Nonactive placebo tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 12-month history of AD and had no significant flares in AD for at least 4 weeks before screening
* inadequate response to a ≥1 month treatment with topical medications
* Atopic dermatitis covering ≥10% of the body surface area
* EASI score ≥16
* Validated Investigator Global Assessment (VIGA) ≥3
* Use of emollient(s) at least 2x daily for 1 week prior to baseline
* Negative coronavirus disease (COVID)-19 results at screening
Exclusion Criteria
* Uncontrolled diabetes
* Stage III or IV cardiac failure
* Severe renal condition
* Major surgery within 8 weeks of screening
* Immunodeficiency and/or receipt of immunosuppressive drugs within 4 weeks of baseline
* Use of systemic Janus kinase (JAK) inhibitor within 8 weeks of baseline
* Received live or live-attenuated vaccine within 4 weeks of baseline
* Prior receipt of RPT193
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RAPT Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cahaba Dermatology and Skin Health Center
Birmingham, Alabama, United States
Perseverance Research Center
Scottsdale, Arizona, United States
Arkansas Research Trials, LLC
North Little Rock, Arkansas, United States
California Dermatology & Clinical Research Institute
Encinitas, California, United States
First OC Dermatology
Fountain Valley, California, United States
Grimes Center
Los Angeles, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Wallace Medical Group
Los Angeles, California, United States
Velocity Clinical Research
North Hollywood, California, United States
Integrative Skin Science and Research
Sacramento, California, United States
Clinical Science Institute
Santa Monica, California, United States
Clinical Trials Research Institute
Thousand Oaks, California, United States
Foxhall Research Center
Washington D.C., District of Columbia, United States
Driven Research LLC
Coral Gables, Florida, United States
Florida Academic Centers Research and Education, LLC
Coral Gables, Florida, United States
Palm Beach Dermatology Group
Delray Beach, Florida, United States
GSI Clinical Research
Margate, Florida, United States
Lenus Research & Medical Group, LLC
Sweetwater, Florida, United States
Forcare Clinical Research
Tampa, Florida, United States
Skin Care Physicians of Georgia
Macon, Georgia, United States
Marietta Dermatology Clinical Research, Inc.
Marietta, Georgia, United States
Georgia Skin & Cancer Clinic
Savannah, Georgia, United States
University Dermatology and Vein Clinic
Darien, Illinois, United States
Indiana Clinical and Translational Sciences Institute (CTSI) Clinical Research Center
Indianapolis, Indiana, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
The Indiana Clinical Trials Center PC
Plainfield, Indiana, United States
Skin Sciences PLLC
Louisville, Kentucky, United States
DelRicht Research
Baton Rouge, Louisiana, United States
Schweiger Dermatology Group, PC Research Division
Columbia, Maryland, United States
MetroBoston Clinical Partners
Brighton, Massachusetts, United States
Beacon Clinical Research, LLC
Quincy, Massachusetts, United States
Fivenson Dermatology
Ann Arbor, Michigan, United States
St. Joseph Dermatology and Vein Clinic
Saint Joseph, Michigan, United States
Grekin Skin Institute
Warren, Michigan, United States
Medisearch Clinical Trials
Saint Joseph, Missouri, United States
Advanced Dermatology of the Midlands
Omaha, Nebraska, United States
Skin Specialists PC (Schlessinger MD)
Omaha, Nebraska, United States
Schweiger Dermatology Group
Verona, New Jersey, United States
Forest Hills Dermatology Group
Kew Gardens, New York, United States
JUVA Skin & Laser Center
New York, New York, United States
Ichan School of Medicine at Mount Sinai
New York, New York, United States
Markowitz Medical, PLLC
New York, New York, United States
Optima Research - Boardman
Boardman, Ohio, United States
Apex Clinical Research Center
Mayfield Heights, Ohio, United States
Health Concepts
Rapid City, South Dakota, United States
Arlington Research Center Inc.
Arlington, Texas, United States
DermResearch
Austin, Texas, United States
Studies in Dermatology, LLC
Cypress, Texas, United States
Dermatology Treatment and Research Center
Dallas, Texas, United States
Clinical Trial Network
Houston, Texas, United States
Progressive Clinical Research
San Antonio, Texas, United States
Acclaim Dermatology
Sugar Land, Texas, United States
Complete Dermatology
Sugar Land, Texas, United States
Jordan Valley Dermatology Center
South Jordan, Utah, United States
West End Dermatology Associates
Richmond, Virginia, United States
Premier Clinical Research
Spokane, Washington, United States
SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario, Canada
LEADER Research
Hamilton, Ontario, Canada
Red Maple Trials Inc.
Ottawa, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RPT193-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.